Status:
COMPLETED
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
Lead Sponsor:
University of Nebraska
Conditions:
Bloodstream Infection
Eligibility:
All Genders
19+ years
Brief Summary
Bloodstream infections (BSI) are a major cause of morbidity and mortality. Bloodstream infections are also costly and result in prolonged hospital stays. The duration of therapy necessary to clear blo...
Detailed Description
Bloodstream infections (BSI) are a major cause of morbidity and mortality. Community-onset BSI have an overall attributable mortality of 10-13% while nosocomial BSI mortality ranges are quite variable...
Eligibility Criteria
Inclusion
- Hospitalized, adult patient, at least one positive blood culture reported within 24 hours of enrollment
Exclusion
- Previously enrolled in the study; discharged/deceased before first positive culture; receiving antibiotic for greater than or equal to 48 hours; endocarditis or osteomyelitis; antithymocyte globulin in the last 12 months; blood cultures positive for coagulase-negative staphylococcus only.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2016
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT00870623
Start Date
June 1 2009
End Date
January 13 2016
Last Update
September 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unversity of Nebraska Medical Center
Omaha, Nebraska, United States, 68198